Chris J. Stern, DBA

Oxygen Biotherapeutics, Inc.

Employing O2, Preserving Life

Oxygen Biotherapeutics, Inc. is listed on the NASDAQ exchange. The company's focus is on developing and marketing oxygen-related therapies for multiple-trauma brain injury and other life or health-threatening situations resulting from a lack of oxygen.

Oxycyte is our unique intravenous emulsion therapy product, a perfluorocarbon (PFC) therapeutic oxygen carrier. It is the first oxygen carrier to treat Traumatic Brain Injury in clinical trials by providing enhanced oxygen delivery to damaged tissues. We believe it ihas the potential to be superior to hemoglobin therapies, in that it appears to be a far better oxygen carrier and does not have the safety issues, such as disease transmission and limited supply, faced by hemoglobin-based products.

Uniqueness of Oxygen Biotherapeutics

At Osygen Biotherapeutics, there is no shortage of ideas when it comes to Oxycyte technology. Potential applications include wound care, treatment for carbon monoxide poisoning, spinal cord injury, decompression sickness ("bends" - of interest to the U.S. Navy), veterinary applications and use  in cosmetics as an anti-aging skin therapy gel.

Potential Oxycyte Applications

The company was founded by Lee Clark, inventor of the heart long machine. In 1990 the company went public under the name Synthetic Blood International. The company was renamed Oxygen Biotherapeutics, Inc. in 2008.

Background

The company's mission is to research, develop, and market oxygen-related therapies.

Our primary goals include making Oxycyte the first oxygen carrier for traumatic brain injury, developing topical oxygen carrier gels, developing a multiple-product portfolio, achieving profitability through licensing, and seeking access to major capital markets. In doing so, the company will set the standard in mitigation of loss of life or health due to lack of oxygen

Vision

We've grown to 21 people now, up from four. Oxycyte is currently in Phase II-b trials, which we expect to be completed in 2011. These trials are being conducted in in Switzerland and Israel. We intend to seek a partner for Phase III. As with most growing biomedical companies, we need more capital to commercialize the products we have under development.

Company Needs

We have an entrepreneurial spirit and consider ourselves to be the "other biomedical company." Sufficient funding is always a challenge in health care product commercialization. The greatest challenge in retail products is in getting products onto retail shelves and into customers' shopping carts.

Enjoyments and Challenges

Stories/Anecdotes